S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Wall Street Insider Makes Prediction about Hot A.I. Stock (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Wall Street Insider Makes Prediction about Hot A.I. Stock (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
52-week Low Names To Tip The Upside Scale In Your Favor
U.S. Loses to China in Shocking WAR GAMES (Ad)
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Wall Street Insider Makes Prediction about Hot A.I. Stock (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Wall Street Insider Makes Prediction about Hot A.I. Stock (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
52-week Low Names To Tip The Upside Scale In Your Favor
U.S. Loses to China in Shocking WAR GAMES (Ad)
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Wall Street Insider Makes Prediction about Hot A.I. Stock (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Wall Street Insider Makes Prediction about Hot A.I. Stock (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
52-week Low Names To Tip The Upside Scale In Your Favor
U.S. Loses to China in Shocking WAR GAMES (Ad)
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Wall Street Insider Makes Prediction about Hot A.I. Stock (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Wall Street Insider Makes Prediction about Hot A.I. Stock (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
52-week Low Names To Tip The Upside Scale In Your Favor
U.S. Loses to China in Shocking WAR GAMES (Ad)
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
NASDAQ:PRPO

Precipio (PRPO) Stock Forecast, Price & News

$5.60
+5.33 (+1,974.07%)
(As of 09/22/2023 ET)
Compare
Today's Range
$4.75
$6.35
50-Day Range
$0.27
$5.60
52-Week Range
$4.75
$20.48
Volume
168,771 shs
Average Volume
236,319 shs
Market Capitalization
$154.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00

Precipio MarketRank™ Forecast

Analyst Rating
0.00 Rating Score
Upside/​Downside
64.3% Downside
$2.00 Price Target
Short Interest
Healthy
0.72% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.22mentions of Precipio in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.85 out of 5 stars


PRPO stock logo

About Precipio (NASDAQ:PRPO) Stock

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; and COVID-19 antibody tests. It sells ICE- technology kits to bio-pharma customers. The company is based in New Haven, Connecticut.

PRPO Price History

PRPO Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Precipio's Earnings: A Preview
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Precipio Announces Q2-2023 Shareholder Update Call
Precipio Shares Growth Catalysts For HemeScreen
Precipio Announces Q1-2023 Shareholder Update Call
Precipio Signs Another HemeScreen™ Customer
See More Headlines
Receive PRPO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precipio and its competitors with MarketBeat's FREE daily newsletter.

PRPO Company Calendar

Last Earnings
8/11/2023
Today
9/23/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRPO
Employees
53
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.00
High Stock Price Forecast
$2.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
-64.3%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-12,200,000.00
Pretax Margin
-98.38%

Debt

Sales & Book Value

Annual Sales
$9.41 million
Book Value
$0.72 per share

Miscellaneous

Free Float
24,640,000
Market Cap
$154.34 million
Optionable
Not Optionable
Beta
2.03
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Ilan DanieliMr. Ilan Danieli (Age 51)
    Founder, Pres, CEO & Director
    Comp: $324.1k
  • Dr. Ayman A. Mohamed M.D. (Age 38)
    Chief Technology Officer
    Comp: $234.1k
  • Mr. Matthew Gage (Age 56)
    Interim Chief Financial Officer
  • Mr. Ahmed Zaki SabetMr. Ahmed Zaki Sabet (Age 36)
    Chief Operating Officer
  • Ms. Miri Chiko-Radomski
    Chief Legal Counsel & People Officer













PRPO Stock - Frequently Asked Questions

What is Precipio's stock price forecast for 2023?

0 Wall Street analysts have issued 1-year target prices for Precipio's shares. Their PRPO share price forecasts range from $2.00 to $2.00. On average, they anticipate the company's share price to reach $2.00 in the next twelve months. This suggests that the stock has a possible downside of 64.3%.
View analysts price targets for PRPO
or view top-rated stocks among Wall Street analysts.

How have PRPO shares performed in 2023?

Precipio's stock was trading at $0.5514 on January 1st, 2023. Since then, PRPO shares have increased by 915.6% and is now trading at $5.60.
View the best growth stocks for 2023 here
.

Are investors shorting Precipio?

Precipio saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 198,400 shares, a drop of 33.0% from the August 15th total of 295,900 shares. Based on an average trading volume of 173,200 shares, the days-to-cover ratio is currently 1.1 days.
View Precipio's Short Interest
.

When is Precipio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our PRPO earnings forecast
.

How were Precipio's earnings last quarter?

Precipio, Inc. (NASDAQ:PRPO) posted its quarterly earnings data on Friday, August, 11th. The biotechnology company reported ($0.09) EPS for the quarter. The biotechnology company had revenue of $3.53 million for the quarter. Precipio had a negative net margin of 98.50% and a negative trailing twelve-month return on equity of 68.54%.

When did Precipio's stock split?

Precipio's stock reverse split on Friday, September 22nd 2023. The 1-20 reverse split was announced on Friday, September 22nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 22nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Precipio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precipio investors own include Biocept (BIOC), Heat Biologics (HTBX), Portola Pharmaceuticals (PTLA), iBio (IBIO), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), VBI Vaccines (VBIV), Co-Diagnostics (CODX), Inpixon (INPX) and Jaguar Health (JAGX).

What is Precipio's stock symbol?

Precipio trades on the NASDAQ under the ticker symbol "PRPO."

Who are Precipio's major shareholders?

Precipio's stock is owned by a number of retail and institutional investors. Top institutional investors include Walleye Capital LLC (9.92%). Insiders that own company stock include Ahmed Zaki Sabet, David Seth Cohen, Ilan Danieli and Richard A Sandberg.
View institutional ownership trends
.

How do I buy shares of Precipio?

Shares of PRPO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Precipio's stock price today?

One share of PRPO stock can currently be purchased for approximately $5.60.

How much money does Precipio make?

Precipio (NASDAQ:PRPO) has a market capitalization of $154.34 million and generates $9.41 million in revenue each year.

How can I contact Precipio?

Precipio's mailing address is 4 Science Park, New Haven CT, 06511. The official website for the company is www.precipiodx.com. The biotechnology company can be reached via phone at (203) 787-7888, via email at investors@precipiodx.com, or via fax at 402-452-5401.

This page (NASDAQ:PRPO) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -